

SVENSK STANDARD

SS-EN ISO 12417-1:2015



Fastställt/Approved: 2015-10-19
Publicerad/Published: 2015-10-21
Utgåva/Edition: 1
Språk/Language: engelska/English
ICS: 11.040.40

Kardiovaskulära implantat och extrakorporala system – produkter som kombinerar medicinsk teknisk produkt med läkemedel –

Del 1: Allmänna krav (ISO 12417-1:2015)

Cardiovascular implants and extracorporeal systems – Vascular device-drug combination products –

Part 1: General requirements (ISO 12417-1:2015)

This preview is downloaded from www.sis.se. Buy the entire standard via <https://www.sis.se/std-8016721>

Standarder får världen att fungera

SIS (Swedish Standards Institute) är en fristående ideell förening med medlemmar från både privat och offentlig sektor. Vi är en del av det europeiska och globala nätverk som utarbetar internationella standarder. Standarder är dokumenterad kunskap utvecklad av framstående aktörer inom industri, näringsliv och samhälle och befrämjar handel över gränser, bidrar till att processer och produkter blir säkrare samt effektiviserar din verksamhet.

Delta och påverka

Som medlem i SIS har du möjlighet att påverka framtida standarder inom ditt område på nationell, europeisk och global nivå. Du får samtidigt tillgång till tidig information om utvecklingen inom din bransch.


Ta del av det färdiga arbetet

Vi erbjuder våra kunder allt som rör standarder och deras tillämpning. Hos oss kan du köpa alla publikationer du behöver – allt från enskilda standarder, tekniska rapporter och standardpaket till handböcker och onlinetjänster. Genom vår webbtjänst e-nav får du tillgång till ett lättnavigerat bibliotek där alla standarder som är aktuella för ditt företag finns tillgängliga. Standarder och handböcker är källor till kunskap. Vi säljer dem.

Utveckla din kompetens och lyckas bättre i ditt arbete

Hos SIS kan du gå öppna eller företagsinterna utbildningar kring innehåll och tillämpning av standarder. Genom vår närhet till den internationella utvecklingen och ISO får du rätt kunskap i rätt tid, direkt från källan. Med vår kunskap om standarders möjligheter hjälper vi våra kunder att skapa verklig nytta och lönsamhet i sina verksamheter.

Vill du veta mer om SIS eller hur standarder kan effektivisera din verksamhet är du välkommen in på www.sis.se eller ta kontakt med oss på tel 08-555 523 00.



Standards make the world go round

SIS (Swedish Standards Institute) is an independent non-profit organisation with members from both the private and public sectors. We are part of the European and global network that draws up international standards. Standards consist of documented knowledge developed by prominent actors within the industry, business world and society. They promote cross-border trade, they help to make processes and products safer and they streamline your organisation.

Take part and have influence

As a member of SIS you will have the possibility to participate in standardization activities on national, European and global level. The membership in SIS will give you the opportunity to influence future standards and gain access to early stage information about developments within your field.

Get to know the finished work

We offer our customers everything in connection with standards and their application. You can purchase all the publications you need from us - everything from individual standards, technical reports and standard packages through to manuals and online services. Our web service e-nav gives you access to an easy-to-navigate library where all standards that are relevant to your company are available. Standards and manuals are sources of knowledge. We sell them.

Increase understanding and improve perception

With SIS you can undergo either shared or in-house training in the content and application of standards. Thanks to our proximity to international development and ISO you receive the right knowledge at the right time, direct from the source. With our knowledge about the potential of standards, we assist our customers in creating tangible benefit and profitability in their organisations.

If you want to know more about SIS, or how standards can streamline your organisation, please visit www.sis.se or contact us on phone +46 (0)8-555 523 00



Europastandarden EN ISO 12417-1:2015 gäller som svensk standard. Detta dokument innehåller den officiella engelska versionen av EN ISO 12417-1:2015.

The European Standard EN ISO 12417-1:2015 has the status of a Swedish Standard. This document contains the official English version of EN ISO 12417-1:2015.

**Förhållandet till övriga delar under samma huvudtitel - Utdrag ur Förord i ISO 12417-1:2015/
Relations to other parts under the same general title - Extract from the Foreword of ISO 12417-1:2015**

ISO 12417 consists of the following parts under the general title, *Cardiovascular implants and extracorporeal systems — Vascular device-drug combination products*:

- *Part 1: General requirements*
- *Part 2: Local regulatory guidance*

© Copyright/Upphovsrätten till denna produkt tillhör SIS, Swedish Standards Institute, Stockholm, Sverige. Användningen av denna produkt regleras av slutanvändarlicensen som återfinns i denna produkt, se standardens sista sidor.

© Copyright SIS, Swedish Standards Institute, Stockholm, Sweden. All rights reserved. The use of this product is governed by the end-user licence for this product. You will find the licence in the end of this document.

Upplysningar om sakinnehållet i standarden lämnas av SIS, Swedish Standards Institute, telefon 08-555 520 00. Standarder kan beställas hos SIS Förlag AB som även lämnar allmänna upplysningar om svensk och utländsk standard.

Information about the content of the standard is available from the Swedish Standards Institute (SIS), telephone +46 8 555 520 00. Standards may be ordered from SIS Förlag AB, who can also provide general information about Swedish and foreign standards.

Denna standard är framtagen av kommittén för Implantat, SIS/TK 340/AG i.

Har du synpunkter på innehållet i den här standarden, vill du delta i ett kommande revideringsarbete eller vara med och ta fram andra standarder inom området? Gå in på www.sis.se - där hittar du mer information.

EUROPEAN STANDARD

EN ISO 12417-1

NORME EUROPÉENNE

EUROPÄISCHE NORM

October 2015

ICS 11.040.40

English Version

**Cardiovascular implants and extracorporeal systems -
Vascular device-drug combination products - Part 1:
General requirements (ISO 12417-1:2015)**

Implants cardiovasculaires et circuits extra-corporels -
Produits de combinaison médicament-dispositif
vasculaire - Partie 1: Exigences générales (ISO 12417-
1:2015)

Kardiovaskuläre Implantate und extrakorporale
Systeme - Vaskuläre Medizinprodukt/Arzneimittel-
Kombinationsprodukte - Teil 1: Allgemeine
Anforderungen (ISO 12417-1:2015)

This European Standard was approved by CEN on 8 August 2015.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Avenue Marnix 17, B-1000 Brussels

Contents

Page

European foreword	2
Introduction	vi
1 Scope	1
2 Normative references	2
3 Terms and definitions	2
4 Intended performance	6
4.1 General.....	6
4.2 Classification.....	6
4.3 Intended clinical location.....	6
5 Design attributes	6
5.1 General.....	6
5.2 Drug-containing part of the VDDCP (DCP).....	7
5.2.1 General.....	7
5.2.2 Matrix.....	7
5.2.3 Active pharmaceutical ingredient (API).....	7
6 Materials	8
7 Design evaluation	8
7.1 General.....	8
7.2 Pre-clinical evaluation.....	9
7.2.1 Sampling.....	9
7.2.2 Conditioning of test samples.....	9
7.2.3 Pre-Clinical <i>in vitro</i> test reports and additional information.....	10
7.2.4 Pre-clinical <i>in vitro</i> evaluation.....	10
7.2.5 Preclinical <i>in vivo</i> evaluation.....	16
7.3 Clinical evaluation.....	21
7.3.1 Purpose.....	21
7.3.2 Specific aims.....	21
7.3.3 Clinical investigation plan.....	21
7.3.4 Data acquisition.....	22
7.3.5 Final report.....	24
7.4 Post-market surveillance.....	25
8 Manufacturing	25
8.1 General.....	25
8.2 Raw material reporting and analysis of the API.....	25
8.3 Raw material analysis and reporting for excipients.....	26
8.4 VDDCP batch release testing.....	27
9 Sterilization	27
9.1 Products supplied sterile.....	27
9.1.1 Testing to support “Sterile” labelling.....	27
9.2 Products supplied non-sterile.....	27
9.3 Sterilization residuals.....	27
10 Packaging	27
10.1 General.....	27
10.2 Considerations for VDDCPs.....	28
10.3 Impact of changes in storage and shipping temperatures on VDDCP.....	28
11 Information supplied by the manufacturer	28
11.1 General.....	28
11.2 Labelling.....	28
11.2.1 VDDCP label(s).....	28
11.2.2 Record label.....	29

11.3 Instructions for use (IFU).....	29
Annex A (informative) Definitions of potential clinical and technical events.....	31
Annex B (informative) Local information regarding submission issues for VDDCPs.....	36
Annex ZA (informative) Relationship between this European Standard and the Essential Requirements of EU Directive 93/42/EEC on medical devices.....	4
Bibliography.....	4

European foreword

This document (EN ISO 12417-1:2015) has been prepared by Technical Committee ISO/TC 150 “Implants for surgery” in collaboration with Technical Committee CEN/TC 285 “Non-active surgical implants” the secretariat of which is held by DIN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by April 2016, and conflicting national standards shall be withdrawn at the latest by April 2016.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN [and/or CENELEC] shall not be held responsible for identifying any or all such patent rights.

This document has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association, and supports essential requirements of EU Directive(s).

For relationship with EU Directive(s), see informative Annex ZA, which is an integral part of this document.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

Endorsement notice

The text of ISO 12417-1:2015 has been approved by CEN as EN ISO 12417-1:2015 without any modification.

Introduction

This part of ISO 12417 was prepared in order to provide minimum requirements for vascular device-drug combination products (VDDCPs).

Only issues related to vascular devices combined with drug(s), wherein the drug serves an ancillary function of the VDDCP are covered by this part of ISO 12417.

It was impossible, when writing this part of ISO 12417, to take into consideration all future and emerging technologies. VDDCPs using such technologies will need to be evaluated following the basic requirements of this International Standard. Testing beyond the scope of this part of ISO 12417 might also be necessary to characterize these device systems. Consideration shall be given to the failure modes of the VDDCP and their effects on the performance in deciding what testing will be appropriate.

For issues related to the primary mode of action (PMOA) of the vascular VDDCP, the reader might find it useful to consider a number of other International Standards (see Bibliography).

Cardiovascular implants and extracorporeal systems — Vascular device-drug combination products —

Part 1: General requirements

1 Scope

This part of ISO 12417 specifies requirements for vascular device-drug combination products (VDDCPs) based upon current technical and medical knowledge. VDDCPs are medical devices with various clinical indications for use in the human vascular blood system. A VDDCP incorporates, as an integral part, substance(s) which, if used separately, can be considered to be a medicinal substance or product (drug substance, drug product) but the action of the medicinal substance is ancillary to that of the device and supports the primary mode of action (PMOA) of the device. With regard to safety, this part of ISO 12417 outlines requirements for intended performance, design attributes, materials, design evaluation, manufacturing, sterilization, packaging, and information supplied by the manufacturer. For implanted products, this International Standard should be considered as a supplement to ISO 14630, which specifies general requirements for the performance of non-active surgical implants. This International Standard should also be considered as a supplement to relevant device-specific standards, such as the ISO 25539-series specifying requirements for endovascular devices. Requirements listed in this part of ISO 12417 also address VDDCPs that are not permanent implants.

NOTE Due to variations in the design of combination products covered by this part of ISO 12417 and due to the relatively recent development of some of these combination products, acceptable standardized *in vitro* test results and clinical study results are not always available. As further scientific and clinical data become available, appropriate revision of this part of ISO 12417 might be necessary.

Delivery systems or parts of the delivery system are included in the scope of this part of ISO 12417, if they comprise an integral component of the vascular device and if they are drug-covered (e.g. drug-covered balloon catheters and drug-covered guidewires).

Devices whose PMOA is to provide a conduit for delivery of a drug, are excluded from the scope of this part of ISO 12417 (e.g. infusion catheters), unless they contain a drug component that is intended to have an ancillary action to the device part (e.g. antimicrobial coated infusion catheter).

Procedures and devices used prior to and following the introduction of the VDDCP (e.g. balloon angioplasty devices) are excluded from the scope of this part of ISO 12417 if they do not affect the drug-related aspects of the device.

This part of ISO 12417 is not comprehensive with respect to the pharmacological evaluation of VDDCPs. Some information on the requirements of different national and regional authorities is given in [Annex B](#).

Absorbable components of VDDCPs (e.g. coatings) are addressed by this part of ISO 12417 in their connection with drug-related aspects of the device. Degradation and other time-dependent aspects of absorbable implants and coatings are not completely addressed by this part of ISO 12417.

NOTE See also ISO/TS 17137 and ASTM F3036-13.

This part of ISO 12417 does not address issues associated with viable or non-viable biological materials such as tissues, cells, or proteins.

This part of ISO 12417 does not address issues associated with active surgical implants (i.e. implants that require power not generated by the human body or gravity).